Mariner
NKTR icon

Mariner’s Nektar Therapeutics NKTR Stock Holding History

Mariner’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-877
Closed -$8.94K – 3617
2025
Q1 		$8.94K Buy
+877
New +$11.5K ﹤0.01% 3416
2023
Q4 		– Sell
-1,269
Closed -$11.3K – 3136
2023
Q3 		$11.3K Buy
+1,269
New +$12.2K ﹤0.01% 2868
2022
Q4 		– Sell
-932
Closed -$45K – 2804
2022
Q3 		$45K Buy
+932
New +$55.4K ﹤0.01% 2321

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner's NKTR Position: Q2 2025 in Review

Mariner sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 877 shares — an estimated $8.94K sold.

Mariner first reported a position in NKTR in Q3 2022 and held it in 3 quarters. The position peaked at $45K in Q3 2022. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Mariner reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mariner sold 877 Nektar Therapeutics shares in Q2 2025, an estimated $8.94K.
  • Mariner first reported a position in Nektar Therapeutics in Q3 2022 and held it in 3 quarters.
  • Mariner's Nektar Therapeutics position peaked at $45K in Q3 2022.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Mariner's 13F filing for Q2 2025, filed 14 Aug 2025.